In short
Overview
Ozempic and Wegovy contain the same molecule. The difference is the licensed indication and the dose, and that is what determines which one you should be on.
Direct Answer
Both are semaglutide. Ozempic is licensed for type 2 diabetes at doses up to 2 mg. Wegovy is licensed for weight management at 2.4 mg, with a 7.2 mg option where more reduction is needed.
For weight loss without diabetes, Wegovy is the correct product. Using the diabetes version for weight loss means a lower dose than the weight trials used.
There is one meaningful extra: both subcutaneous and oral semaglutide are approved for reducing major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
Who This Applies To
- Type 2 diabetes, weight loss secondary: the diabetes product may be appropriate, and there are additional options
- Weight management without diabetes: the weight management product at weight management doses
- Established cardiovascular disease without diabetes: semaglutide is the preferred agent of the whole class, because it is the only one with proven cardiovascular benefit in this group
- Wanting maximum weight loss: tirzepatide beat semaglutide 2.4 mg in a head to head trial, though the higher 7.2 mg semaglutide dose was not included
Option Comparison / Decision Criteria
The practical differences
| Ozempic | Wegovy | |
| Molecule | Semaglutide | Semaglutide |
| Licensed for | Type 2 diabetes | Weight management |
| Maximum dose | 2 mg weekly | 2.4 mg, or 7.2 mg weekly |
| Cardiovascular indication | In diabetes with established disease | In established disease with obesity or overweight |
How the dose is built up
Semaglutide starts at 0.25 mg weekly for four weeks, then increases at four week intervals through 0.5, 1 and 1.7 mg to 1.7 or 2.4 mg weekly. Where 2.4 mg has been tolerated for at least four weeks and more reduction is wanted, a higher dose can be considered.
The slow build up is not caution for its own sake. It is what makes the nausea manageable.
How much weight, realistically
In a trial at 68 weeks, semaglutide 2.4 mg produced a mean change of minus 15.8 per cent against minus 6.4 per cent for liraglutide 3 mg.
In a network meta analysis, semaglutide 2.4 mg had the greatest odds of at least 5 per cent weight loss, with an odds ratio of 9.82, and the largest percentage change in body weight.
Where tirzepatide sits
Tirzepatide is generally the most effective agent for weight loss and beat semaglutide 2.4 mg head to head. In SURMOUNT-1, tirzepatide 15 mg produced 20.9 per cent mean weight loss at 72 weeks, and 57 per cent of that group lost 20 per cent or more.
But if you have established cardiovascular disease and no diabetes, semaglutide is still preferred, because it has proven cardiovascular benefit and tirzepatide does not in that population.
Why an In-Person Physician Review Matters
Why the label matters more than the molecule Because it determines the dose you can reach.
The weight loss figures people quote come from trials at weight management doses. A diabetes product used off label for weight loss tops out lower. It also determines what is monitored. In diabetes, weight loss can cause low blood sugar, particularly on insulin or sulfonylureas. Doses of those are often reduced during the first four weeks and adjusted from glucose readings after that. What gets checked and when Contact every four to six weeks initially, to check tolerance and adjust dose Review every two to three months for weight, vital signs and side effects Watch for nausea, vomiting, diarrhoea, constipation, reflux, pancreatitis and gallbladder problems Slower dose increases and monitoring for anyone with diabetic retinopathy The decision point at 12 weeks If less than 4 to 5 per cent of body weight has gone after 12 weeks at the maximum tolerated dose, the medication is normally stopped and a different one tried, rather than continued indefinitely. The exception is someone whose weight was rising and stopped rising. That counts as a response.
Frequently Asked Questions
Same molecule, semaglutide. Different licensed indication and different maximum dose: up to 2 mg for the diabetes product, 2.4 mg or 7.2 mg for the weight management one.
It is used that way, but the dose tops out lower than the weight management doses the trials were run at, so you would not expect the same results. Where weight is the indication, the weight management product is the correct one.
For weight loss generally, yes. It beat semaglutide 2.4 mg head to head, and in SURMOUNT-1 the 15 mg dose gave 20.9 per cent mean loss at 72 weeks. But with established cardiovascular disease and no diabetes, semaglutide is preferred for its proven cardiovascular benefit.
About 16 to 20 weeks, because the dose rises in four week steps from 0.25 mg. That gradual build up is what keeps the nausea manageable.
Evidence
Where this information comes from
Every figure on this page is taken from the sources below. All of them are free to read, so you can check them yourself.
- Wegovy: European public assessment report
- Semaglutide for managing overweight and obesity
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
- Obesity and overweight
This page is general medical information and does not replace a personal consultation. Trial results are averages across large groups, not a prediction for any one person.